Baseline characteristics of CAD patients enrolled for analysis of the basal platelet lipidome
| CAD patient characteristics . | CAD (n = 107) . |
|---|---|
| Age (mean ± SD) | 71.2 (± 10.7) |
| Male gender | 79 (73.8%) |
| LVEF% at admission (mean ± SD) | 51.9 (± 11.2) |
| Cardiovascular risk factors | |
| Arterial hypertension | 86 (80.4%) |
| Hyperlipidemia | 52 (48.6%) |
| Diabetes mellitus type 2 | 31 (29.0%) |
| Smoking | 19 (17.8%) |
| Medication on admission | |
| ASA | 54 (50.5%) |
| Clopidogrel | 12 (11.2%) |
| Prasugrel | 4 (3.7%) |
| Ticagrelor | 12 (11.2%) |
| ACE inhibitors | 56 (52.3%) |
| ARBs | 26 (24.3%) |
| β blockers | 73 (68.2%) |
| Statins | 73 (68.2%) |
| Reason of admission/clinical diagnosis | |
| ACS | 26 (24.3%) |
| CCS | 81 (75.7%) |
| Plasma lipid profile | |
| Total cholesterol (mg/dL) | 161.3 (± 45.4) |
| LDL cholesterol (mg/dL) | 96.2 (± 34.4) |
| HDL cholesterol (mg/dL) | 48.6 (± 17.4) |
| Triglycerides (mg/dL) | 145.3 (± 84.5) |
| CAD patient characteristics . | CAD (n = 107) . |
|---|---|
| Age (mean ± SD) | 71.2 (± 10.7) |
| Male gender | 79 (73.8%) |
| LVEF% at admission (mean ± SD) | 51.9 (± 11.2) |
| Cardiovascular risk factors | |
| Arterial hypertension | 86 (80.4%) |
| Hyperlipidemia | 52 (48.6%) |
| Diabetes mellitus type 2 | 31 (29.0%) |
| Smoking | 19 (17.8%) |
| Medication on admission | |
| ASA | 54 (50.5%) |
| Clopidogrel | 12 (11.2%) |
| Prasugrel | 4 (3.7%) |
| Ticagrelor | 12 (11.2%) |
| ACE inhibitors | 56 (52.3%) |
| ARBs | 26 (24.3%) |
| β blockers | 73 (68.2%) |
| Statins | 73 (68.2%) |
| Reason of admission/clinical diagnosis | |
| ACS | 26 (24.3%) |
| CCS | 81 (75.7%) |
| Plasma lipid profile | |
| Total cholesterol (mg/dL) | 161.3 (± 45.4) |
| LDL cholesterol (mg/dL) | 96.2 (± 34.4) |
| HDL cholesterol (mg/dL) | 48.6 (± 17.4) |
| Triglycerides (mg/dL) | 145.3 (± 84.5) |
CAD (n = 107) patients were enrolled separately for lipidomic analysis of washed platelets isolated from arterial blood collected during percutaneous coronary intervention (PCI) procedure.70 Administration of antiplatelet therapy and statin were considered from the record of medications upon admission.